Spyre Current Deferred Revenue from 2010 to 2026
| SYRE Stock | 36.68 0.05 0.14% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 594.5 K | Current Value 564.8 K | Quarterly Volatility 5.1 M |
Check Spyre Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spyre Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 855.5 K, Gross Profit of 757.5 K or Other Operating Expenses of 251.8 M, as well as many indicators such as Price To Sales Ratio of 158, Dividend Yield of 0.0 or PTB Ratio of 2.31. Spyre financial statements analysis is a perfect complement when working with Spyre Therapeutics Valuation or Volatility modules.
Spyre | Current Deferred Revenue | Build AI portfolio with Spyre Stock |
Analyzing Spyre Therapeutics's Current Deferred Revenue over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Current Deferred Revenue has evolved provides context for assessing Spyre Therapeutics's current valuation and future prospects.
Latest Spyre Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Spyre Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Spyre Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spyre Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Spyre Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 2,694,375 | |
| Geometric Mean | 371,084 | |
| Coefficient Of Variation | 190.79 | |
| Mean Deviation | 3,780,574 | |
| Median | 517,000 | |
| Standard Deviation | 5,140,667 | |
| Sample Variance | 26.4T | |
| Range | 13.4M | |
| R-Value | 0.15 | |
| Mean Square Error | 27.6T | |
| R-Squared | 0.02 | |
| Significance | 0.57 | |
| Slope | 150,062 | |
| Total Sum of Squares | 422.8T |
Spyre Current Deferred Revenue History
About Spyre Therapeutics Financial Statements
Spyre Therapeutics stakeholders use historical fundamental indicators, such as Spyre Therapeutics' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Spyre Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Spyre Therapeutics' assets and liabilities are reflected in the revenues and expenses on Spyre Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Spyre Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 594.5 K | 564.8 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:Check out the analysis of Spyre Therapeutics Correlation against competitors. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Will Biotechnology sector continue expanding? Could Spyre diversify its offerings? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spyre Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Spyre Therapeutics requires distinguishing between market price and book value, where the latter reflects Spyre's accounting equity. The concept of intrinsic value - what Spyre Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spyre Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spyre Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.